Clinical Trial Update: THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. [Phase 3]

View source ↗

Summary

THOR Phase 3 trial evaluating continued trastuzumab (Herceptin) with second-line chemotherapy in HER2-positive metastatic breast cancer; results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-10-24